NEW YORK, March 15 – Oxford Glycosciences of Oxford, UK, has apparently changed its plans for entering the protein microarray market, saying Thursday that their collaboration with Packard Biosciences and Cambridge Antibody Technologies is “just a research project” and that the company has no immediate plans to commercialize the technology. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.